• Dec 09, 2024

What's Going On With Cardiff Oncology Stock On Tuesday?

On Tuesday, Cardiff Oncology, Inc. (NASDAQ:CRDF) revealed initial data from the CRDF-004 Phase 2 trial, which evaluates onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation. Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:

  • Dec 09, 2024

Johnson Outdoors Shares Slide After Q4 Earnings Miss, Hit By Market Challenges And Lower Margins

Johnson Outdoors Inc (NASDAQ:JOUT) shares plunged after the company reported its fourth-quarter 2024 results. The company’s sales grew 9.9% year-over-year to $105.9 million, missing the consensus of $114.99 million. Loss per share was $3.35, missing the consensus loss of $0.98. Gross margin contracted 600 bps to 23.5%, primarily due to higher promotional discounts, a shift in product mix favoring lower-margin items, and inventory reserves for slow-moving and obsolete stock. Gross profit was down

  • Dec 09, 2024

Ferguson Maintains FY25 Guidance Amid Tough Market, Q1 Misses Estimates

Ferguson Enterprises Inc. (NYSE:FERG) shares are trading lower after the company reported first-quarter results. The company reported net sales of $7.77 billion, which was 0.8% higher year over year, missing the consensus of $7.83 billion. Organic revenue fell by 0.3%, with a 1.1% negative impact from acquisition growth. Net sales in the U.S. business increased by 0.5%, while that in Canada grew by 6.3%. Gross margin contracted by 10 basis points to 30.1% in the first quarter. Adjusted operating

  • Dec 09, 2024

Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?

On Monday, Chimerix (NASDAQ:CMRX) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end. A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the most common primary brain tumor. Chimerix stock is trading higher on a strong session volume of 4.31 million, compared to an ave